AR012427A1 - Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn - Google Patents
Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adnInfo
- Publication number
- AR012427A1 AR012427A1 ARP980101722A ARP980101722A AR012427A1 AR 012427 A1 AR012427 A1 AR 012427A1 AR P980101722 A ARP980101722 A AR P980101722A AR P980101722 A ARP980101722 A AR P980101722A AR 012427 A1 AR012427 A1 AR 012427A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- human
- modified
- tnf alpha
- molecule
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000008836 DNA modification Effects 0.000 title 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 9
- 102000057041 human TNF Human genes 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una molécula de TNF alfa humano modificada capaz de incitar anticuerpos neutralizantes hacia el TNF alfa humano del tipo sin cultivar, luego de laadministracion de dicha molécula de TNF alfa modificada a un huésped humano, donde por lo menosu n fragmento de péptido de la molécula de TNF alfa humanoha sido sustituido por un péptido como mínimo que, segun se sabe, contiene un epitopo de células T inmuno-dominante o una forma truncada de dicha moléculaque contiene un epitopo inmuno-dominan te, y una o ambas regiones flanqueadoras de la molécula de TNF alfa humano que comprende por lo menos un epitopo decélula B de TNF alfa, donde la sustitucion introduce un cambio sustancial en la secuencia de aminoácidos de la lámina betafrontal, en uno cualesquiera delos bucles conectores y/o en uno cualesquiera de los filamentos B, I o D de la lámina beta posterior. Las moléculas de TNF alfa humano modificadas o el ADNque las codifica pueden formularse como vacunas contra el TNFalfa, opcionalmente con adyuvantes farmacéuticamente aceptables, para la prevenciono el tratamiento de enfermedades inflamatorias cronicas, tales como artritis reumatoide y enfermedades inflamatorias de los intestinos, cáncer,esclerosisdiseminada, diabetes, psoriasis, osteoporosis o asma. Los fluidos humanos pueden ser sometidos a prueba para detectar la presencia de TNF alfa porcontacto con una composicion que contenga al TNF alfa modificado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK41897 | 1997-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012427A1 true AR012427A1 (es) | 2000-10-18 |
Family
ID=8093298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101722A AR012427A1 (es) | 1997-04-15 | 1998-04-15 | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7118750B1 (es) |
| EP (1) | EP0975668B1 (es) |
| JP (1) | JP2001521386A (es) |
| KR (1) | KR100522289B1 (es) |
| CN (1) | CN1178955C (es) |
| AR (1) | AR012427A1 (es) |
| AT (1) | ATE326481T1 (es) |
| AU (1) | AU743400B2 (es) |
| BR (1) | BR9811462A (es) |
| CA (1) | CA2289476A1 (es) |
| CZ (1) | CZ9903657A3 (es) |
| DE (1) | DE69834556T2 (es) |
| DK (1) | DK0975668T3 (es) |
| EE (1) | EE9900461A (es) |
| ES (1) | ES2264569T3 (es) |
| HR (1) | HRP980203B1 (es) |
| HU (1) | HUP0001930A3 (es) |
| IL (1) | IL132281A0 (es) |
| NO (1) | NO995002L (es) |
| NZ (1) | NZ337955A (es) |
| PL (1) | PL194221B1 (es) |
| RU (1) | RU2241715C2 (es) |
| SI (1) | SI0975668T1 (es) |
| SK (1) | SK285639B6 (es) |
| TR (1) | TR199902562T2 (es) |
| TW (1) | TW510921B (es) |
| UA (1) | UA72440C2 (es) |
| WO (1) | WO1998046642A1 (es) |
| ZA (1) | ZA983148B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| DK1159003T3 (da) * | 1999-03-02 | 2011-02-07 | Centocor Inc | Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| HUP0201861A3 (en) | 1999-07-20 | 2004-07-28 | Pharmexa As | Method for down-regulating gdf-8 activity |
| WO2001097837A1 (en) * | 2000-06-21 | 2001-12-27 | Ferring Bv | Solubilised protein vaccines |
| EP1485122A2 (en) * | 2002-03-11 | 2004-12-15 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| FR2844514B1 (fr) | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| PL378571A1 (pl) * | 2003-02-01 | 2006-05-02 | Neuralab Limited | Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß |
| AU2005220156B2 (en) | 2004-02-27 | 2011-06-02 | Vaxconsulting | Peptides of IL1 beta and TNF alpha and method of treatment using same |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| MX2007014440A (es) | 2005-05-16 | 2008-02-11 | Abbott Biotech Ltd | Uso de inhibidor de tnf para tratamiento de poliartritis erosiva. |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| CA2698920A1 (en) * | 2007-09-25 | 2009-04-02 | Intervet International B.V. | Vaccine for the treatment of osteoarthritis |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CN102666588A (zh) | 2009-11-05 | 2012-09-12 | Uab研究基金会 | 治疗基底细胞样基因型癌症 |
| WO2011116344A2 (en) | 2010-03-18 | 2011-09-22 | The Uab Research Foundation | Targeting cancer stem cells |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| MX2013006501A (es) | 2010-12-08 | 2014-02-28 | Neovacs | Vacuna fuertemente inactivada y todavia sumamente inmunogenica, y proceso para su fabricacion. |
| CN102539778A (zh) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 |
| JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性Ａ−βに対する抗体を生成させるための能動免疫 |
| CN103376327A (zh) * | 2012-04-28 | 2013-10-30 | 通用电气公司 | 检测抗体或融合蛋白的浓度的方法 |
| ES2912989T3 (es) | 2015-05-05 | 2022-05-30 | Rubicon Biotechnology Llc | Inmunoterapia para cáncer |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE107362T1 (de) | 1986-06-20 | 1994-07-15 | Dainippon Pharmaceutical Co | Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns. |
| DE3843534A1 (de) * | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU634379B2 (en) | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
-
1998
- 1998-04-15 ES ES98916866T patent/ES2264569T3/es not_active Expired - Lifetime
- 1998-04-15 HR HR980203A patent/HRP980203B1/xx not_active IP Right Cessation
- 1998-04-15 EP EP98916866A patent/EP0975668B1/en not_active Expired - Lifetime
- 1998-04-15 KR KR10-1999-7009504A patent/KR100522289B1/ko not_active Expired - Fee Related
- 1998-04-15 SK SK1409-99A patent/SK285639B6/sk unknown
- 1998-04-15 CN CNB988042142A patent/CN1178955C/zh not_active Expired - Fee Related
- 1998-04-15 NZ NZ337955A patent/NZ337955A/xx unknown
- 1998-04-15 ZA ZA9803148A patent/ZA983148B/xx unknown
- 1998-04-15 TR TR1999/02562T patent/TR199902562T2/xx unknown
- 1998-04-15 AT AT98916866T patent/ATE326481T1/de not_active IP Right Cessation
- 1998-04-15 WO PCT/DK1998/000157 patent/WO1998046642A1/en not_active Ceased
- 1998-04-15 PL PL98336295A patent/PL194221B1/pl not_active IP Right Cessation
- 1998-04-15 RU RU99122686/13A patent/RU2241715C2/ru not_active IP Right Cessation
- 1998-04-15 SI SI9830845T patent/SI0975668T1/sl unknown
- 1998-04-15 UA UA99116210A patent/UA72440C2/uk unknown
- 1998-04-15 AU AU70303/98A patent/AU743400B2/en not_active Ceased
- 1998-04-15 CZ CZ19993657A patent/CZ9903657A3/cs unknown
- 1998-04-15 EE EEP199900461A patent/EE9900461A/xx unknown
- 1998-04-15 JP JP54338798A patent/JP2001521386A/ja active Pending
- 1998-04-15 BR BR9811462-0A patent/BR9811462A/pt not_active Application Discontinuation
- 1998-04-15 AR ARP980101722A patent/AR012427A1/es unknown
- 1998-04-15 DE DE69834556T patent/DE69834556T2/de not_active Expired - Fee Related
- 1998-04-15 US US09/060,294 patent/US7118750B1/en not_active Expired - Fee Related
- 1998-04-15 DK DK98916866T patent/DK0975668T3/da active
- 1998-04-15 IL IL13228198A patent/IL132281A0/xx unknown
- 1998-04-15 HU HU0001930A patent/HUP0001930A3/hu unknown
- 1998-04-15 CA CA002289476A patent/CA2289476A1/en not_active Abandoned
- 1998-07-20 TW TW087111808A patent/TW510921B/zh not_active IP Right Cessation
-
1999
- 1999-10-14 NO NO995002A patent/NO995002L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012427A1 (es) | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn | |
| UY23762A1 (es) | Procedimiento de preparacion de lipopeptidos procedentes de actinoplanes sp. con efecto farmacologigo y sus usos | |
| CN104470943B (zh) | 新肽及其用途 | |
| AR062895A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| ES2573337T3 (es) | Apelina pegilada y usos de la misma | |
| UY28289A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores | |
| Lin et al. | IL-4 modulates macrophage polarization in ankylosing spondylitis | |
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| CO6251321A2 (es) | Polipeptidos dominios variable s de anticuerpos y antagonistas | |
| BR112012019881A2 (pt) | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 | |
| AR045710A1 (es) | Uso de inhibidores de tnf alfa y composiciones farmaceuticas que los comprenden para el tratamiento a dosis bajas | |
| ES2730050T3 (es) | Interleuquina 38 truncada en el extremo terminal N | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| Luo et al. | The role of monocyte/macrophage chemokines in pathogenesis of osteoarthritis: A review | |
| Shuai et al. | Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis | |
| AR008387A1 (es) | Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas | |
| CR20200487A (es) | Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos | |
| AR083546A1 (es) | Tratamiento de inflamacion gastrointestinal, soriasis y asma | |
| DE69534044D1 (de) | Menschliches beta-9 chemokin | |
| BR122012018280B8 (pt) | composição farmacêutica compreendendo hormônio luteinizante humano e sacarose | |
| Cobos et al. | Peptides derived from hookworm anti-inflammatory proteins suppress inducible colitis in mice and inflammatory cytokine production by human cells | |
| Yang et al. | The emerging spectrum of early life exposure-related inflammation and epigenetic therapy | |
| Lee et al. | Clonorchis sinensis-derived protein attenuates inflammation and new bone formation in ankylosing spondylitis | |
| Ptitsyn | Invariant features of globin primary structure and coding of their secondary structure | |
| ES2091752T3 (es) | Medios y procedimiento para la obtencion de un polipeptido de la interleucina-1 alfa humana, recombinante. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |